Register for OXB’s Capital Markets Event: 2 June 2026

News: OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category

Justifying a Pathway to Reduced Replication-Competent Lentivirus (RCL) Testing: Adding the Empirical to the Theoretical

May 20, 2026